Alternative/JJ
Splicing/NN
and/CC
Its/PRP$
Impact/NN
as/IN
a/DT
Cancer/NN
Diagnostic/JJ
Marker/NN
./.
====================
Most/JJS
genes/NNS
are/VBP
processed/VBN
by/IN
alternative/JJ
splicing/NN
for/IN
gene/NN
expression/NN
,/,
resulting/VBG
in/IN
the/DT
complexity/NN
of/IN
the/DT
transcriptome/JJ
in/IN
eukaryotes/NNS
./.
====================
It/PRP
allows/VBZ
a/DT
limited/JJ
number/NN
of/IN
genes/NNS
to/TO
encode/VB
various/JJ
proteins/NNS
with/IN
intricate/JJ
functions/NNS
./.
====================
Alternative/JJ
splicing/NN
is/VBZ
regulated/VBN
by/IN
genetic/JJ
mutations/NNS
in/IN
cis-regulatory/JJ
factors/NNS
and/CC
epigenetic/JJ
events/NNS
./.
====================
Furthermore/RB
,/,
splicing/NN
events/NNS
occur/VBP
differently/RB
according/VBG
to/TO
cell/NN
type/NN
,/,
developmental/JJ
stage/NN
,/,
and/CC
various/JJ
diseases/NNS
,/,
including/VBG
cancer/NN
./.
====================
Genome/DT
instability/NN
and/CC
flexible/JJ
proteomes/VBZ
by/IN
alternative/JJ
splicing/NN
could/MD
affect/VB
cancer/NN
cells/NNS
to/TO
grow/VB
and/CC
survive/VBP
,/,
leading/VBG
to/TO
metastasis/NN
./.
====================
Cancer/NN
cells/NNS
that/WDT
are/VBP
transformed/VBN
by/IN
aberrant/JJ
and/CC
uncontrolled/JJ
mechanisms/NNS
could/MD
produce/VB
alternative/JJ
splicing/NN
to/TO
maintain/VB
and/CC
spread/VBN
them/PRP
continuously/RB
./.
====================
Splicing/NN
variants/NNS
in/IN
various/JJ
cancers/NNS
represent/VBP
crucial/JJ
roles/NNS
for/IN
tumorigenesis/NN
./.
====================
Taken/VBN
together/RB
,/,
the/DT
identification/NN
of/IN
alternative/JJ
spliced/VBN
variants/NNS
as/IN
biomarkers/NNS
to/TO
distinguish/VB
between/IN
normal/JJ
and/CC
cancer/NN
cells/NNS
could/MD
cast/JJ
light/JJ
on/IN
tumorigenesis/NN
./.
====================
Genes/NNS
are/VBP
transcribed/VBN
into/IN
pre-mRNA/NN
and/CC
pass/NN
through/IN
splicing/NN
as/IN
a/DT
post-transcriptional/JJ
modification/NN
to/TO
generate/VB
mature/JJ
mRNA/NN
for/IN
translation/NN
[/(
1/CD
]/)
./.
====================
Splicing/VBG
is/VBZ
an/DT
essential/JJ
process/NN
for/IN
gene/NN
expression/NN
in/IN
eukaryotes/NNS
,/,
eliminating/VBG
introns/NNS
and/CC
joining/VBG
the/DT
exons/NNS
,/,
which/WDT
occurs/VBZ
in/IN
the/DT
spliceosome/NN
,/,
a/DT
complex/JJ
of/IN
small/JJ
nuclear/JJ
ribonucleoproteins/NNS
(/(
snRNPs/NNS
)/)
and/CC
other/JJ
proteins/NNS
[/(
2/CD
]/)
./.
====================
This/DT
splicing/NN
can/MD
generate/VB
alternative/JJ
spliced/VBN
transcripts/NNS
from/IN
pre-mRNA/NN
and/CC
different/JJ
exon/NN
constitutions/NNS
,/,
resulting/VBG
in/IN
different/JJ
proteins/NNS
./.
====================
Alternative/JJ
splicing/NN
can/MD
occur/VB
in/IN
different/JJ
ways/NNS
./.
====================
The/DT
most/JJS
representative/JJ
mechanisms/NNS
are/VBP
as/IN
follows/VBZ
:/:
1/CD
,/,
extending/VBG
or/CC
shortening/VBG
the/DT
exon/NN
by/IN
alternative/JJ
donor/NN
and/CC
acceptor/NN
sites/NNS
;/:
2/CD
,/,
exon/NN
skipping/VBG
;/:
3/CD
,/,
mutual/JJ
exon/NN
exclusion/NN
;/:
and/CC
4/CD
,/,
intron/NN
retention/NN
[/(
1/CD
,/,
3/CD
,/,
4/CD
]/)
./.
====================
These/DT
mechanisms/NNS
allow/VBP
protein/NN
isoforms/NNS
with/IN
different/JJ
biological/JJ
characters/NNS
to/TO
be/VB
produced/VBN
from/IN
single/JJ
genes/NNS
[/(
1/CD
]/)
./.
====================
Therefore/RB
,/,
complex/NN
transcriptomes/VBZ
and/CC
proteomes/VBZ
could/MD
be/VB
derived/VBN
from/IN
a/DT
limited/JJ
number/NN
of/IN
genes/NNS
[/(
4/CD
]/)
./.
====================
Namely/RB
,/,
this/DT
process/NN
is/VBZ
an/DT
important/JJ
strategy/NN
for/IN
the/DT
complicated/VBN
regulation/NN
of/IN
eukaryotes/NNS
,/,
and/CC
most/JJS
genes/NNS
(/(
92-95/CD
%/NN
)/)
undergo/VBP
this/DT
process/NN
[/(
5/CD
,/,
6/CD
]/)
./.
====================
Alternative/JJ
splicing/NN
is/VBZ
regulated/VBN
according/VBG
to/TO
cell/NN
type/NN
,/,
developmental/JJ
stage/NN
,/,
and/CC
disease/NN
states/NNS
[/(
1/CD
,/,
7/CD
,/,
8/CD
]/)
./.
====================
Biochemical/JJ
mechanisms/NNS
for/IN
the/DT
recognition/NN
of/IN
splice/NN
sites/NNS
are/VBP
not/RB
understood/VBN
clearly/RB
according/VBG
to/TO
cellular/JJ
conditions/NNS
,/,
but/CC
some/DT
tissue-specific/JJ
factors/NNS
participate/VBP
in/IN
alternative/JJ
splicing/NN
[/(
4/CD
]/)
./.
====================
In/IN
addition/NN
,/,
quantitative/JJ
gene/NN
expression/NN
is/VBZ
controlled/VBN
by/IN
nonsense-mediated/JJ
decay/NN
mechanisms/NNS
that/WDT
degrade/VBP
targeting/VBG
mRNAs/NNS
,/,
producing/VBG
nonsense/JJ
mutations/NNS
./.
====================
Thus/RB
,/,
truncated/VBN
or/CC
erroneous/JJ
proteins/NNS
with/IN
abnormal/JJ
functions/NNS
are/VBP
prevented/VBN
from/IN
being/VBG
expressed/VBN
[/(
9/CD
]/)
./.
====================
Alternative/JJ
transcripts/NNS
could/MD
be/VB
related/JJ
to/TO
various/JJ
diseases/NNS
,/,
including/VBG
cancer/NN
./.
====================
As/IN
many/JJ
as/IN
50/CD
%/NN
of/IN
genetic/JJ
diseases/NNS
of/IN
humans/NNS
are/VBP
related/JJ
to/TO
mutations/NNS
in/IN
splice/NN
site/NN
sequences/NNS
and/CC
regulatory/JJ
elements/NNS
,/,
such/JJ
enhancers/NNS
and/CC
silencers/NNS
,/,
resulting/VBG
in/IN
alternative/JJ
exon/NN
constitution/NN
[/(
3/CD
,/,
10/CD
,/,
11/CD
]/)
./.
====================
Recently/RB
,/,
the/DT
SpliceDisease/NN
database/NN
,/,
providing/VBG
information/NN
for/IN
relationships/NNS
among/IN
gene/NN
mutation/NN
,/,
splicing/NN
defects/NNS
,/,
and/CC
diseases/NNS
,/,
was/VBD
reported/VBN
[/(
12/CD
]/)
./.
====================
Especially/RB
,/,
aberrent/JJ
spliced/VBN
variants/NNS
are/VBP
found/VBN
frequently/RB
in/IN
cancer/NN
,/,
indicating/VBG
that/IN
they/PRP
could/MD
play/VB
a/DT
role/NN
for/IN
the/DT
survival/NN
of/IN
cancer/NN
cells/NNS
[/(
8/CD
]/)
./.
====================
Alternative/JJ
splicing/NN
of/IN
cancer-related/JJ
genes/NNS
could/MD
affect/VB
cell/NN
cycle/NN
control/NN
,/,
signal/NN
transduction/NN
pathways/NNS
,/,
apoptosis/NN
,/,
angiogenesis/NN
,/,
invasion/NN
,/,
and/CC
metastasis/NN
[/(
8/CD
,/,
13/CD
]/)
./.
====================
Cancer/NN
markers/NNS
allow/VBP
us/PRP
to/TO
determine/VB
the/DT
prognosis/NN
and/CC
therapy/NN
for/IN
cancer/NN
during/IN
the/DT
remedy/NN
of/IN
cancer/NN
./.
====================
Thus/RB
,/,
the/DT
identification/NN
of/IN
cancer/NN
markers/NNS
is/VBZ
highlighted/VBN
in/IN
the/DT
cancer/NN
research/NN
field/NN
[/(
14/CD
]/)
./.
====================
Cancers/NNS
result/NN
from/IN
the/DT
accumulation/NN
of/IN
complex/NN
genetic/JJ
and/CC
epigenetic/JJ
alterations/NNS
against/IN
normal/JJ
regulation/NN
./.
====================
Cancerous/JJ
cells/NNS
grow/VBP
irregularly/RB
,/,
create/VBP
malignant/JJ
tumors/NNS
,/,
and/CC
move/VB
to/TO
the/DT
other/JJ
parts/NNS
of/IN
the/DT
body/NN
./.
====================
Their/PRP$
alternative/JJ
spliced/VBN
transcripts/NNS
could/MD
be/VB
detected/VBN
with/IN
cryptic/JJ
splicing/NN
sites/NNS
./.
====================
Accordingly/RB
,/,
alternative/JJ
transcripts/NNS
produced/VBN
by/IN
splicing/NN
events/NNS
represent/VBP
good/JJ
candidates/NNS
for/IN
cancer/NN
biomarkers/NNS
[/(
7/CD
,/,
8/CD
,/,
13/CD
]/)
./.
====================
In/IN
the/DT
present/JJ
review/NN
,/,
we/PRP
summarize/VBP
and/CC
discuss/VBP
the/DT
alternative/JJ
splicing/NN
events/NNS
and/CC
their/PRP$
potential/JJ
as/IN
cancer/NN
biomarkers/NNS
./.
====================
Alternative/JJ
splicing/NN
is/VBZ
an/DT
essential/JJ
post-transcriptional/JJ
process/NN
for/IN
creating/VBG
various/JJ
protein/NN
isoforms/NNS
from/IN
the/DT
same/JJ
gene/NN
./.
====================
Approximately/RB
60/CD
%/NN
of/IN
human/JJ
genes/NNS
have/VBP
at/IN
least/JJS
one/CD
alternative/JJ
splice/NN
transcript/NN
[/(
15/CD
]/)
./.
====================
Alternative/JJ
splicing/NN
is/VBZ
regulated/VBN
by/IN
mutations/NNS
in/IN
genetic/JJ
regions/NNS
[/(
3/CD
,/,
7/CD
,/,
14/CD
]/)
./.
====================
Most/JJS
exons/NNS
are/VBP
flanked/VBN
by/IN
the/DT
intronic/JJ
dinucleotides/NNS
GT/NN
(/(
donor/NN
site/NN
)/)
and/CC
AG/NN
(/(
acceptor/NN
site/NN
)/)
,/,
which/WDT
are/VBP
recognized/VBN
by/IN
the/DT
spliceosome/NN
(/(
Fig/NN
./.
====================
1A/NN
)/)
./.
====================
Pre-mRNA/NN
is/VBZ
reconstructed/VBN
only/RB
by/IN
joined/VBN
exons/NNS
with/IN
the/DT
removal/NN
of/IN
introns/NNS
./.
====================
However/RB
,/,
mutations/NNS
of/IN
these/DT
splice/NN
sites/NNS
lead/VBP
to/TO
aberrant/JJ
splicing/NN
,/,
producing/VBG
exon/NN
skipping/NN
and/CC
different/JJ
joining/VBG
of/IN
exons/NNS
to/TO
truncated/VBN
or/CC
nonfunctional/JJ
or/CC
dysfunctional/JJ
proteins/NNS
./.
====================
It/PRP
was/VBD
reported/VBN
that/IN
mutations/NNS
of/IN
splice/NN
sites/NNS
may/MD
play/VB
important/JJ
roles/NNS
in/IN
human/JJ
disease/NN
,/,
and/CC
longer/RBR
proteins/NNS
also/RB
tend/VBP
to/TO
associate/VB
to/TO
various/JJ
disease/NN
[/(
16/CD
,/,
17/CD
]/)
./.
====================
In/IN
the/DT
case/NN
of/IN
the/DT
PAX6/NN
gene/NN
,/,
a/DT
5/CD
'/``
splice/NN
site/NN
mutation/NN
in/IN
intron/NN
12/CD
induces/VBZ
exon/NN
skipping/NN
in/IN
relation/NN
to/TO
autosomal/JJ
dominant/JJ
aniridia/NN
[/(
18/CD
]/)
./.
====================
In/IN
the/DT
APC/NN
gene/NN
,/,
abnormal/JJ
splicing/NN
by/IN
a/DT
3/CD
'/``
splice/NN
site/NN
mutation/NN
in/IN
intron/NN
3/CD
causes/VBZ
exon/NN
4/CD
skipping/VBG
due/JJ
to/TO
a/DT
frameshift/NN
in/IN
hepatoblastoma/NN
[/(
19/CD
]/)
./.
====================
A/DT
mutation/NN
in/IN
intron/NN
25/CD
of/IN
the/DT
ABCA3/NN
gene/NN
creates/VBZ
novel/JJ
5/CD
'/``
splice/NN
sites/NNS
[/(
20/CD
]/)
./.
====================
The/DT
spliceosome/NN
is/VBZ
known/VBN
to/TO
recognize/VB
cryptic/JJ
splice/NN
sites/NNS
instead/RB
of/IN
typical/JJ
splice/NN
sites/NNS
./.
====================
Noncanonical/JJ
splice/NN
sites/NNS
are/VBP
GC-AG/NN
,/,
GG-AG/NN
,/,
GT-TG/NN
,/,
GT-CG/NN
,/,
AT-AG/NN
,/,
GA-AG/NN
,/,
GT-AC/NN
,/,
and/CC
CT-AG/NN
(/(
5'-3/NN
'/``
splice/NN
sites/NNS
)/)
[/(
21-23/CD
]/)
./.
====================
Mutations/NNS
at/IN
the/DT
noncanonical/JJ
splice/NN
site/NN
of/IN
the/DT
SEDL/NN
gene/NN
cause/VBP
variants/NNS
in/IN
X-linked/JJ
spondyloepiphyseal/JJ
dysplasia/NN
tarda/NN
[/(
24/CD
]/)
./.
====================
Additionally/RB
,/,
less/RBR
exon/NN
skipping/VBG
and/CC
more/RBR
intron/NN
retention/NN
by/IN
alternative/JJ
splice/NN
sites/NNS
are/VBP
observed/VBN
in/IN
cancer/NN
tissue/NN
compared/VBN
to/TO
normal/JJ
tissues/NNS
from/IN
an/DT
analysis/NN
of/IN
expression/NN
sequence/NN
tags/NNS
(/(
ESTs/NNS
)/)
[/(
25/CD
]/)
./.
====================
As/IN
a/DT
mutation/NN
of/IN
pre-mRNA/NN
,/,
A/DT
to/TO
I/NN
RNA/NN
editing/VBG
(/(
conversion/NN
adenosine/NN
to/TO
inosine/VB
from/IN
deamination/NN
)/)
also/RB
affects/VBZ
transcriptome/JJ
diversification/NN
./.
====================
RNA/NN
editing/VBG
has/VBZ
regulatory/JJ
roles/NNS
,/,
such/JJ
as/IN
altering/VBG
splice/NN
sites/NNS
and/CC
sequences/NNS
necessary/JJ
for/IN
recognition/NN
of/IN
the/DT
spliceosome/NN
,/,
resulting/VBG
in/IN
modulation/NN
of/IN
alternatively/RB
spliced/VBN
transcripts/NNS
[/(
26/CD
]/)
./.
====================
The/DT
last/JJ
case/NN
of/IN
alternative/JJ
splicing/NN
is/VBZ
by/IN
cis-genomic/JJ
mutations/NNS
in/IN
regulatory/JJ
factors/NNS
,/,
such/JJ
as/IN
branch/DT
sites/NNS
,/,
exonic/JJ
and/CC
intronic/JJ
splicing/NN
enhancers/NNS
,/,
and/CC
silencers/NNS
[/(
7/CD
,/,
27/CD
]/)
./.
====================
Pre-mRNA/NN
has/VBZ
exonic/JJ
and/CC
intronic/JJ
splicing/NN
enhancers/NNS
(/(
ESEs/NNS
,/,
ISEs/NNS
)/)
and/CC
silencers/NNS
(/(
ESSs/NNS
,/,
ISSs/NNS
)/)
that/WDT
promote/VBP
exon/NN
inclusion/NN
and/CC
exclusion/NN
by/IN
regulation/NN
of/IN
splice/NN
site/NN
recognition/NN
,/,
respectively/RB
(/(
Fig/NN
./.
====================
1A/NN
)/)
./.
====================
The/DT
arginine-serine-rich/JJ
(/(
SR/JJ
)/)
protein/NN
that/WDT
binds/VBZ
to/TO
ESEs/NNS
induces/VBZ
splicing/NN
via/IN
a/DT
helping/JJ
assembly/NN
spliceosome/NN
by/IN
interacting/VBG
with/IN
snRNP/NN
./.
====================
On/IN
the/DT
contrary/JJ
,/,
heterogeneous/JJ
nuclear/JJ
ribonucleoprotein/NN
is/VBZ
bound/VBN
to/TO
ESEs/NNS
and/CC
ISEs/NNS
and/CC
inhibits/VBZ
splice/NN
site/NN
recognition/NN
by/IN
blocking/VBG
spliceosome/NN
assembly/NN
[/(
15/CD
,/,
27-29/CD
]/)
./.
====================
Mutations/NNS
in/IN
regulatory/JJ
factor/NN
could/MD
disturb/VB
the/DT
binding/NN
of/IN
these/DT
spliceosome/NN
assembly-related/VBN
proteins/NNS
./.
====================
Mutations/NNS
at/IN
nucleotide/NN
positions/NNS
57/CD
and/CC
58/CD
of/IN
the/DT
174-bp-long/JJ
exon/NN
7/CD
cause/VBP
exon/NN
7/CD
skipping/VBG
as/IN
a/DT
result/NN
of/IN
aberrant/JJ
splicing/NN
by/IN
interrupted/JJ
ESE-specific/JJ
consensus/NN
sequences/NNS
that/WDT
are/VBP
recognized/VBN
by/IN
the/DT
SC35/NN
and/CC
SF2/ASF/NN
SR/JJ
proteins/NNS
[/(
10/CD
,/,
30/CD
]/)
./.
====================
Additionally/RB
,/,
Ron/NNP
,/,
encoding/VBG
the/DT
tyrosine/NN
kinase/NN
receptor/NN
for/IN
macrophage-stimulating/VBG
protein/NN
,/,
has/VBZ
alternative/JJ
splice/NN
transcripts/NNS
./.
====================
It/PRP
is/VBZ
regulated/VBN
by/IN
overexpression/NN
of/IN
SF2/ASF/NN
binding/NN
to/TO
ESE/NN
and/CC
ISE/NN
in/IN
colon/NN
and/CC
breast/NN
cancer/NN
[/(
31/CD
]/)
./.
====================
Alternative/JJ
splicing/NN
is/VBZ
also/RB
known/VBN
to/TO
be/VB
affected/VBN
by/IN
epigenetic/JJ
regulation/NN
,/,
such/JJ
as/IN
DNA/NN
methylation/NN
,/,
histone/NN
modification/NN
,/,
and/CC
chromatin/NN
structure/NN
(/(
Fig/NN
./.
====================
1B/NN
)/)
./.
====================
The/DT
relationship/NN
between/IN
chromatin/NN
structure/NN
and/CC
alternative/JJ
splicing/NN
is/VBZ
still/RB
in/IN
a/DT
maze/JJ
,/,
but/CC
association/NN
studies/NNS
are/VBP
gradually/RB
increasing/VBG
genomewide/NN
[/(
32-34/CD
]/)
./.
====================
Hisone/NN
modifications/NNS
are/VBP
enriched/VBN
in/IN
exons/NNS
rather/RB
than/IN
introns/NNS
and/CC
related/JJ
to/TO
exon/NN
expression/NN
,/,
especially/RB
H3K36me3/NN
,/,
H3K79me1/NN
,/,
H2BK5me1/NN
,/,
H3K27me1/NN
,/,
H3K27me2/NN
,/,
and/CC
H3K27me3/NN
[/(
35/CD
,/,
36/CD
]/)
./.
====================
H3K36me3/NN
marking/VBG
in/IN
exons/NNS
is/VBZ
found/VBN
in/IN
weakly/RB
expressed/VBN
,/,
alternatively/RB
spliced/VBN
exons/NNS
,/,
indicating/VBG
that/IN
histone/NN
modification/NN
has/VBZ
a/DT
relation/NN
to/TO
transcription/NN
via/IN
splicing-related/VBN
marking/VBG
mechanisms/NNS
[/(
36/CD
,/,
37/CD
]/)
./.
====================
These/DT
histone/NN
marks/NNS
could/MD
recruit/VB
splicing/NN
regulators/NNS
with/IN
chromatin/NN
binding/NN
proteins/NNS
and/CC
affect/VB
mRNA/NN
splicing/NN
[/(
33/CD
]/)
./.
====================
Additionally/RB
,/,
hisone/NN
acethylation/NN
could/MD
modulate/VB
splicing/NN
rates/NNS
to/TO
react/VB
quickly/RB
to/TO
changing/VBG
conditions/NNS
with/IN
increased/VBN
RNA/NN
polymerase/NN
II/CD
processivity/NN
,/,
and/CC
spliceosome/NN
rearrangements/NNS
are/VBP
affected/VBN
by/IN
histone/NN
acetylation/NN
[/(
38/CD
]/)
./.
====================
Nevertheless/RB
,/,
although/IN
there/EX
is/VBZ
little/JJ
evidence/NN
,/,
DNA/NN
methylation/NN
has/VBZ
been/VBN
reported/VBN
to/TO
have/VB
a/DT
relationship/NN
with/IN
splice/NN
sites/NNS
./.
====================
CpG/NN
dinucleotides/NNS
are/VBP
distributed/VBN
nonrandomly/RB
in/IN
the/DT
genome/NN
./.
====================
Exon/NN
skipping/VBG
and/CC
mutually/RB
exclusive/JJ
exons/NNS
have/VBP
significantly/RB
lower/JJR
levels/NNS
of/IN
both/DT
CG/NN
and/CC
mCG/NN
in/IN
the/DT
exonic/JJ
regions/NNS
,/,
whereas/IN
intron/NN
retention/NN
has/VBZ
significantly/RB
higher/JJR
levels/NNS
of/IN
CG/NN
in/IN
both/DT
exonic/JJ
and/CC
intronic/JJ
regions/NNS
[/(
34/CD
]/)
./.
====================
A/DT
DNA-binding/JJ
protein/NN
,/,
CCCTC-binding/JJ
factor/NN
(/(
CTCF/NN
)/)
,/,
was/VBD
inhibited/VBN
by/IN
a/DT
methylation/NN
event/NN
of/IN
CD45/NN
exon/NN
5/CD
[/(
39/CD
]/)
./.
====================
These/DT
epigenetic/JJ
features/NNS
are/VBP
strongly/RB
associated/VBN
with/IN
alternative/JJ
splicing/NN
./.
====================
Furthermore/RB
,/,
these/DT
mechanisms/NNS
are/VBP
known/VBN
to/TO
be/VB
changed/VBN
according/VBG
to/TO
cell/NN
type/NN
and/CC
disease/NN
states/NNS
./.
====================
Especially/RB
,/,
in/IN
cancer/NN
,/,
the/DT
epigenetic/JJ
regulation/NN
of/IN
chromatin/NN
structure/NN
effects/NNS
aberrant/JJ
gene/NN
expression/NN
by/IN
alternative/JJ
splicing/NN
in/IN
cancer/NN
[/(
1/CD
,/,
7/CD
,/,
8/CD
]/)
./.
====================
Taken/VBN
together/RB
,/,
gene/NN
expression/NN
via/IN
alternative/JJ
splicing/NN
is/VBZ
altered/JJ
by/IN
complicated/VBN
and/CC
mutual/JJ
mechanisms/NNS
,/,
from/IN
genetic/JJ
to/TO
epigenetic/JJ
regulation/NN
./.
====================
Therefore/RB
,/,
it/PRP
casts/NNS
light/NN
on/IN
the/DT
understanding/NN
of/IN
cancer/NN
mechanisms/NNS
by/IN
an/DT
investigation/NN
of/IN
alternative/JJ
splicing/NN
patterns/NNS
./.
====================
A/DT
number/NN
of/IN
studies/NNS
have/VBP
been/VBN
reported/VBN
that/IN
alternative/JJ
splicing/NN
is/VBZ
related/JJ
closely/RB
to/TO
development/NN
,/,
cellular/JJ
stress/NN
,/,
and/CC
various/JJ
diseases/NNS
,/,
including/VBG
cancer/NN
,/,
as/IN
a/DT
crucial/JJ
contributor/NN
to/TO
transcriptome/VB
and/CC
proteome/JJ
diversity/NN
[/(
1/CD
,/,
7/CD
,/,
8/CD
,/,
14/CD
]/)
./.
====================
In/IN
cancer/NN
,/,
with/IN
increasing/VBG
genomic/JJ
instability/NN
,/,
sequence/NN
substitution/NN
and/CC
aberrant/JJ
alternative/JJ
splicing/NN
occur/VBP
frequently/RB
,/,
leading/VBG
to/TO
erroneous/JJ
and/CC
dysfunctional/JJ
proteins/NNS
[/(
14/CD
]/)
./.
====================
Protein/NN
isoforms/NNS
made/VBD
from/IN
this/DT
process/NN
are/VBP
developmentally/RB
regulated/VBN
and/CC
preferentially/RB
re-expressed/VBN
in/IN
cancer/NN
and/CC
help/VB
the/DT
differentiation/NN
and/CC
survival/NN
of/IN
cancer/NN
cells/NNS
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
The/DT
development/NN
of/IN
genomewide/NN
analysis/NN
allows/VBZ
large-scale/JJ
examination/NN
of/IN
the/DT
relationship/NN
between/IN
alternative/JJ
splicing/NN
and/CC
tumorigenesis/NN
[/(
40/CD
,/,
41/CD
]/)
./.
====================
Every/RB
case/NN
of/IN
alternative/JJ
splicing/NN
is/VBZ
reported/VBN
in/IN
cancer/NN
;/:
among/IN
these/DT
,/,
the/DT
most/JJS
frequent/JJ
case/NN
is/VBZ
the/DT
mutually/RB
exclusive/JJ
exon/NN
[/(
14/CD
]/)
./.
====================
For/IN
example/NN
,/,
overexpression/NN
of/IN
CD44/NN
,/,
involved/VBN
in/IN
cell/NN
proliferation/NN
,/,
differentiation/NN
,/,
migration/NN
,/,
and/CC
alternative/JJ
splicing/NN
,/,
by/IN
different/JJ
splice/NN
sites/NNS
of/IN
CD44/NN
during/IN
tumorigenesis/NN
indicates/VBZ
that/IN
it/PRP
could/MD
play/VB
roles/NNS
in/IN
tumor/NN
cell/NN
invasion/NN
and/CC
metastasis/NN
[/(
42-45/CD
]/)
./.
====================
Tumor/NN
suppressor/NN
genes/NNS
,/,
such/JJ
as/IN
p53/NN
and/CC
PTEN/NN
(/(
Phosphatase/NN
and/CC
Tensin/NN
homolog/NN
,/,
deleted/VBN
on/IN
chromosome/NN
TEN/NN
)/)
,/,
have/VBP
splicing/NN
variants/NNS
associated/VBN
to/TO
cancer/NN
[/(
46/CD
]/)
./.
====================
p53/NN
protein/NN
isoforms/NNS
through/IN
alternative/JJ
splicing/NN
have/VBP
critical/JJ
roles/NNS
in/IN
many/JJ
biological/JJ
processes/NNS
,/,
indicating/VBG
that/IN
dysregulation/NN
effects/NNS
tumorigenesis/NN
[/(
47/CD
]/)
./.
====================
Different/JJ
expression/NN
of/IN
PTEN/NN
and/CC
its/PRP$
alternatively/RB
spliced/VBN
transcripts/NNS
are/VBP
found/VBN
to/TO
vary/VB
in/IN
different/JJ
tissue/NN
types/NNS
./.
====================
PTEN/NN
regulates/VBZ
p53/NN
stability/NN
and/CC
in/IN
turn/NN
regulates/VBZ
its/PRP$
own/JJ
transcriptional/JJ
activity/NN
./.
====================
The/DT
PTEN/NN
splice/NN
variants/NNS
retained/VBD
in/IN
intron/NN
3/CD
region/NN
and/CC
intron/NN
5/CD
region/NN
have/VBP
been/VBN
found/VBN
in/IN
breast/NN
cancer/NN
[/(
46/CD
]/)
./.
====================
In/IN
the/DT
case/NN
of/IN
the/DT
APC/NN
gene/NN
,/,
aberrant/JJ
splice/NN
skipping/NN
of/IN
exon/NN
4/CD
,/,
created/VBD
by/IN
insertion/NN
of/IN
T/NN
in/IN
intron/NN
4/CD
,/,
is/VBZ
involved/VBN
in/IN
colon/NN
cancer/NN
[/(
48/CD
]/)
./.
====================
An/DT
alternative/JJ
5/CD
'/``
splice/NN
site/NN
in/IN
BCL-X/NN
results/NNS
in/IN
2/CD
isoforms/NNS
,/,
long/JJ
and/CC
short/JJ
(/(
Bcl-x/NN
(/(
L/NN
)/)
,/,
Bcl-x/NN
(/(
X/NN
)/)
)/)
,/,
which/WDT
have/VBP
contrasting/VBG
functions/NNS
related/JJ
to/TO
apoptosis/NN
and/CC
are/VBP
overexpressed/VBN
in/IN
various/JJ
tumors/NNS
[/(
49/CD
,/,
50/CD
]/)
./.
====================
Although/IN
specific/JJ
roles/NNS
of/IN
vascular/JJ
endothelial/JJ
growth/NN
factor/NN
(/(
VEGF/NN
)/)
isoforms/NNS
are/VBP
not/RB
known/VBN
exactly/RB
,/,
among/IN
the/DT
isoforms/NNS
of/IN
VEGF4/NN
involved/VBN
in/IN
formation/NN
of/IN
new/JJ
vessels/NNS
,/,
VEGF165/NNP
and/CC
VEGF165b/NN
,/,
created/VBD
by/IN
an/DT
alternative/JJ
3/CD
'/``
splice/NN
site/NN
,/,
have/VBP
different/JJ
expression/NN
in/IN
cancer/NN
[/(
51/CD
,/,
52/CD
]/)
./.
====================
Over/RB
40/CD
different/JJ
MDM2/NN
transcripts/NNS
are/VBP
identified/VBN
in/IN
normal/JJ
and/CC
cancer/NN
by/IN
alternative/JJ
5/CD
'/``
and/CC
3/CD
'/``
splice/NN
sites/NNS
./.
====================
They/PRP
mostly/RB
lose/VBP
the/DT
p53/NN
binding/NN
domain/NN
and/CC
promote/VBP
tumor/NN
progression/NN
and/CC
affect/VB
prognosis/NN
independently/RB
[/(
53/CD
,/,
54/CD
]/)
./.
====================
Increasing/VBG
number/NN
of/IN
reports/NNS
have/VBP
demonstrated/VBN
the/DT
expression/NN
of/IN
aberrant/JJ
and/CC
abnormal/JJ
splice/NN
variants/NNS
in/IN
cancer/NN
cells/NNS
or/CC
tissues/NNS
./.
====================
However/RB
,/,
it/PRP
is/VBZ
not/RB
enough/IN
evidence/NN
for/IN
a/DT
functional/JJ
relationship/NN
between/IN
alternative/JJ
splicing/NN
and/CC
cancer/NN
./.
====================
Hallmarks/NNS
of/IN
the/DT
initiation/NN
and/CC
early/JJ
growth/NN
of/IN
cancers/NNS
during/IN
tumor/NN
progression/NN
using/VBG
large-scale/JJ
analyses/NNS
of/IN
splicing/NN
variants/NNS
in/IN
the/DT
cancer/NN
EST/NN
database/NN
are/VBP
needed/VBN
as/IN
new/JJ
RNA/NN
prognosis/NN
markers/NNS
./.
====================
Cancer/NN
is/VBZ
an/DT
uncontrolled/JJ
state/NN
and/CC
irregularly/RB
altered/JJ
genetically/RB
and/CC
epigenetically/RB
compared/VBN
to/TO
normal/JJ
regulation/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
For/IN
this/DT
reason/NN
,/,
many/JJ
studies/NNS
have/VBP
made/VBN
an/DT
effort/NN
to/TO
identify/VB
specific/JJ
features/NNS
and/CC
regulation/NN
mechanims/NNS
of/IN
various/JJ
diseases/NNS
,/,
including/VBG
cancer/NN
./.
====================
It/PRP
is/VBZ
important/JJ
and/CC
necessary/JJ
to/TO
identify/VB
cancer/NN
markers/NNS
to/TO
be/VB
able/JJ
to/TO
distinguish/VB
between/IN
cancer/NN
and/CC
normal/JJ
cells/NNS
./.
====================
Cancer/NN
markers/NNS
could/MD
be/VB
very/RB
helpful/JJ
in/IN
understanding/VBG
tumorigenesis/NN
and/CC
developing/VBG
tumor/NN
targets/NNS
for/IN
therapeutic/JJ
intervention/NN
./.
====================
However/RB
,/,
there/EX
still/RB
remain/VBP
unsolved/JJ
problems/NNS
in/IN
spite/NN
of/IN
a/DT
number/NN
of/IN
studies/NNS
[/(
7/CD
,/,
14/CD
,/,
45/CD
,/,
64/CD
]/)
./.
====================
From/IN
this/DT
point/NN
of/IN
view/NN
,/,
alternatively/RB
spliced/VBN
transcripts/NNS
by/IN
mutation/NN
and/CC
cryptic/JJ
splice/NN
site/NN
altered/JJ
expression/NN
levels/NNS
in/IN
cancer/NN
have/VBP
emerged/VBN
as/IN
strong/JJ
candidates/NNS
of/IN
cancer/NN
biomarker/NN
at/IN
the/DT
mRNA/NN
and/CC
protein/NN
level/NN
[/(
7/CD
]/)
./.
====================
As/IN
written/RB
previously/RB
,/,
some/DT
alternative/JJ
transcripts/NNS
of/IN
several/JJ
genes/NNS
,/,
CD44/NN
,/,
p53/NN
,/,
PTEN/NN
,/,
BCL-X/NN
,/,
VEGF4/NN
,/,
and/CC
MDM2/NN
,/,
have/VBP
been/VBN
discovered/VBN
(/(
see/VB
also/RB
Table/JJ
1/CD
)/)
[/(
43/CD
,/,
46/CD
,/,
49/CD
,/,
50/CD
,/,
52/CD
,/,
54/CD
]/)
./.
====================
They/PRP
are/VBP
also/RB
associated/VBN
with/IN
various/JJ
cancers/NNS
directly/RB
or/CC
indirectly/RB
./.
====================
Recently/RB
,/,
the/DT
discovery/NN
of/IN
biomarkers/NNS
has/VBZ
improved/VBN
by/IN
genomewide/NN
analysis/NN
[/(
13/CD
,/,
65/CD
,/,
66/CD
]/)
./.
====================
It/PRP
could/MD
be/VB
expected/VBN
to/TO
provide/VB
valuable/JJ
information/NN
for/IN
the/DT
association/NN
between/IN
alternative/JJ
splice/NN
variants/NNS
and/CC
cancers/NNS
./.
====================
Thus/RB
,/,
novel/JJ
candidate/NN
variants/NNS
could/MD
contribute/VB
to/TO
the/DT
development/NN
of/IN
diagnostic/JJ
,/,
prognostic/JJ
,/,
and/CC
therapeutic/JJ
markers/NNS
./.
====================
RNA/NN
splicing/NN
is/VBZ
a/DT
core/NN
mechanism/NN
to/TO
generate/VB
mature/JJ
mRNA/NN
for/IN
translation/NN
,/,
and/CC
alternative/JJ
splicing/NN
is/VBZ
an/DT
indispensable/JJ
mechanism/NN
,/,
stratgically/RB
leading/VBG
to/TO
protein/NN
diversity/NN
for/IN
complicated/VBN
regulation/NN
in/IN
eukaryotes/NNS
./.
====================
In/IN
cancer/NN
,/,
alternative/JJ
splicing/NN
is/VBZ
more/RBR
flexible/JJ
,/,
leading/VBG
various/JJ
proteins/NNS
with/IN
aberrant/JJ
functions/NNS
to/TO
promote/VB
growth/NN
and/CC
the/DT
spread/VBN
of/IN
cancer/NN
cells/NNS
./.
====================
It/PRP
is/VBZ
important/JJ
to/TO
identify/VB
alternative/JJ
transcripts/NNS
that/WDT
function/NN
specifically/RB
in/IN
cancer/NN
./.
====================
These/DT
alternative/JJ
transcripts/NNS
could/MD
be/VB
used/VBN
not/RB
only/RB
as/IN
diagnostic/JJ
biomarkers/NNS
but/CC
also/RB
prognostic/JJ
and/CC
theraputic/JJ
biomarkers/NNS
./.
====================
Therefore/RB
,/,
studies/NNS
on/IN
genetic/JJ
and/CC
epigenetic/JJ
regulation/NN
in/IN
relation/NN
to/TO
alternative/JJ
splice/NN
variants/NNS
in/IN
cancer/NN
could/MD
open/JJ
new/JJ
windows/VBZ
of/IN
research/NN
in/IN
answering/VBG
unsolved/JJ
questions/NNS
of/IN
tumorigenesis/NN
./.
====================
Genetic/JJ
and/CC
epigenetic/JJ
regulation/NN
of/IN
alternative/JJ
splicing/NN
./.
====================
(/(
A/DT
)/)
Most/JJS
genes/NNS
are/VBP
spliced/VBN
by/IN
typical/JJ
splice/NN
sites/NNS
(/(
GT-AG/NN
)/)
and/CC
regulatory/JJ
sequences/NNS
in/IN
exons/NNS
(/(
ESS/NN
and/CC
ESE/NN
)/)
and/CC
introns/NNS
(/(
ISS/NN
and/CC
ISE/NN
)/)
./.
====================
Mutations/NNS
(/(
*/LS
)/)
generate/VBP
alternative/JJ
splicing/NN
,/,
resulting/VBG
in/IN
various/JJ
transcripts/NNS
from/IN
a/DT
single/JJ
gene/NN
./.
====================
(/(
B/NN
)/)
H3K36me3/NN
marking/VBG
in/IN
exons/NNS
is/VBZ
found/VBN
in/IN
weakly/RB
expressed/VBN
alternatively/RB
spliced/VBN
exons/NNS
(/(
grey/PRP
thin/DT
dotted/JJ
line/NN
)/)
,/,
and/CC
H3K4me3/NN
marks/NNS
are/VBP
rich/JJ
in/IN
spliced/VBN
exons/NNS
(/(
black/JJ
thick/JJ
dotted/JJ
line/NN
)/)
,/,
indicating/VBG
that/IN
histone/NN
modification/NN
has/VBZ
a/DT
relation/NN
to/TO
transcription/NN
via/IN
splicing-related/VBN
marking/VBG
mechanisms/NNS
./.
====================
Additionally/RB
,/,
hisone/NN
acethylation/NN
could/MD
modulate/VB
splicing/NN
rates/NNS
to/TO
react/VB
quickly/RB
to/TO
changing/VBG
conditions/NNS
with/IN
increased/VBN
RNA/NN
polymerase/NN
II/CD
processivity/NN
,/,
and/CC
spliceosome/NN
rearrangements/NNS
are/VBP
affected/VBN
by/IN
histone/NN
acetylation/NN
./.
====================
High/JJ
levels/NNS
of/IN
CG/NN
have/VBP
a/DT
tendency/NN
not/RB
to/TO
be/VB
spliced/VBN
(/(
grey/PRP
line/NN
in/IN
intron/NN
)/)
,/,
and/CC
exon/NN
skipping/VBG
is/VBZ
in/IN
the/DT
lower/JJR
level/NN
of/IN
both/DT
CG/NN
and/CC
mCG/NN
in/IN
exonic/JJ
regions/NNS
./.
====================
Methylation/NN
of/IN
exon/NN
inhibits/VBZ
binding/NN
of/IN
CCCTC-binding/JJ
factor/NN
(/(
CTCF/NN
)/)
,/,
leading/VBG
to/TO
exon/NN
skipping/NN
./.
====================
ESE/NN
,/,
exonic/JJ
splicing/NN
enhancers/NNS
;/:
ISE/NN
,/,
intronic/JJ
splicing/NN
enhancers/NNS
;/:
ESS/NN
,/,
exonic/JJ
and/CC
intronic/JJ
splicing/NN
silencers/NNS
;/:
ISS/NN
,/,
intronic/JJ
splicing/NN
silencers/NNS
;/:
SR/JJ
,/,
arginine-serine-rich/WDT
;/:
RNP/NN
,/,
ribonucleoprotein/NN
./.
====================
Roles/NNS
of/IN
alternative/JJ
splicing/NN
in/IN
cancer/NN
./.
====================
Dysfunctional/JJ
proteins/NNS
are/VBP
generated/VBN
by/IN
alternative/JJ
splicing/NN
in/IN
cancer-related/JJ
genes/NNS
(/(
oncogenic/JJ
and/CC
tumor/NN
suppressor/NN
genes/NNS
)/)
,/,
increasing/VBG
genomic/JJ
instability/NN
./.
====================
These/DT
aberrant/JJ
proteins/NNS
help/VBP
cancerous/JJ
cells/NNS
to/TO
promote/VB
their/PRP$
growth/NN
,/,
proliferation/NN
,/,
and/CC
metastasis/NN
continuously/RB
(/(
tumorigenesis/NN
)/)
./.
====================
Variants/NNS
of/IN
cancer-related/JJ
genes/NNS
expressed/VBN
specifically/RB
or/CC
differently/RB
with/IN
their/PRP$
crucial/JJ
roles/NNS
for/IN
tumorigenesis/NN
could/MD
be/VB
potential/JJ
biomarkers/NNS
to/TO
distinguish/VB
between/IN
normal/JJ
and/CC
cancer/NN
cells/NNS
./.
====================
Alternative/JJ
spliced/VBN
transcript/NN
related/JJ
to/TO
cancer/NN
====================
